HENLIUS (02696) announced that the supplemental application for new indications of its self-developed Hanlikang® (Rituximab Injection) has been approved by the National Medical Products Administration (NMPA). The newly approved indications are for the treatment of previously untreated adult patients with diffuse large B-cell lymphoma (DLBCL) in combination with polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone; and for the treatment of adult patients with relapsed or refractory DLBCL who are unsuitable for hematopoietic stem cell transplantation, in combination with bendamustine and polatuzumab vedotin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments